Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. develops clinical-stage biotechnology programs for hematologic diseases, led by burixafor (GPC-100), a highly selective small-molecule CXCR4 antagonist. Company updates center on burixafor's role in hematopoietic stem cell mobilization for multiple myeloma transplant settings, sickle cell disease, cell and gene therapy support, and acute myeloid leukemia chemosensitization.
Recurring news also covers clinical data presentations and publications, collaborations for combination approaches, financial results, liquidity disclosures, and research spending following Exicure's acquisition of GPCR Therapeutics USA. Earlier company context includes its historical focus on nucleic acid therapies and restructuring before the current hematology-focused pipeline.
Exicure, a biotechnology company focused on gene therapy, announced its participation in two significant scientific conferences in November 2021. At TIDES EU, Bart Anderson will present on the development of Spherical Nucleic Acids targeting SCN9A for neuropathic pain on November 16. Additionally, at Neuroscience 2021, presentations will include research on Spherical Nucleic Acids targeting frataxin in Friedreich’s ataxia and their biodistribution in mouse models. Exicure is advancing its therapeutic candidates, including XCUR-FXN for Friedreich’s ataxia and cavrotolimod for advanced solid tumors.
Exicure, Inc. (NASDAQ: XCUR), a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, has announced its participation in two scientific conferences this October. The 17th International Congress on Neuronal Ceroid Lipofuscinosis will feature a presentation on Spherical Nucleic Acids targeting CLN3 for Batten Disease by Grant Corbett on October 8, 2021. Additionally, the International Oligonucleotides and Peptides Conference will see Matthias Schroff discussing their technology on October 18, 2021. Exicure focuses on innovative treatments for various neurological and genetic disorders.
Exicure (NASDAQ: XCUR), a leader in gene regulatory drugs, will present at the Chardan Virtual 5th Annual Genetic Medicines Conference on October 5, 2021, from 11:00 AM to 11:25 AM ET. Attendees can access the presentation via a live webcast. The session will also be available for replay for 30 days afterward. Exicure is focused on therapeutics for various diseases, including Friedreich’s ataxia and advanced solid tumors, leveraging its proprietary Spherical Nucleic Acid technology.
Exicure, Inc. (NASDAQ: XCUR), a biotechnology company focused on gene regulatory and immunotherapeutic innovations, announced that CEO David Giljohann will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 3:20 PM ET. Attendees can register for a free spectator pass and access the live stream here. Exicure is advancing SNA technology for treating various neurological and genetic disorders.
Exicure, Inc. (NASDAQ: XCUR), a leader in gene regulatory and immunotherapeutic drugs, has announced its participation in two scientific conferences in September 2021. These events include TIDES USA 2021, where Exicure will present research on the biodistribution of Spherical Nucleic Acids (SNA) in rats, and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society, focusing on SNA targeting FXN for treating Friedreich's Ataxia. Posters will be available on Exicure's website after the events.
Exicure is based in Chicago and Cambridge, developing therapeutics for various genetic disorders.
Exicure, Inc. (NASDAQ: XCUR), a biotechnology company, announced its participation in key investor conferences for September 2021. The events include Citi’s 16th Annual Biopharma Conference from September 8-10, the H.C. Wainwright 23rd Annual Global Investment Conference with a presentation on September 13 at 7:00 AM ET, and the Baird Global Healthcare Conference on September 14 at 9:40 AM ET. The company is focused on developing therapeutics using its Spherical Nucleic Acid technology, with candidates targeting Friedreich’s ataxia and advanced solid tumors.
Exicure, Inc. (NASDAQ:XCUR) reported its financial results for Q2 2021, highlighting collaborations and advancements in its neurology pipeline. A $20 million upfront payment from Ipsen for Huntington’s disease and Angelman syndrome collaboration reinforces its financial stability, with potential for up to $1 billion in milestones. Research & Development expenses rose to $10.8 million, contributing to a net loss of $14.3 million. Despite increased losses, the company maintains sufficient liquidity, expecting to fund operations for at least 12 months due to existing cash and new partnership inflows.
Exicure, Inc. (NASDAQ: XCUR) has released an update on the Phase 1b/2 clinical trial of cavrotolimod (AST-008), targeting advanced solid tumors. Interim data shows that 26 patients have been dosed in the Phase 2 stage, with 17 evaluable patients. Notably, one patient with Merkel cell carcinoma (MCC) achieved a complete response, allowing for continued enrollment in the study. The overall response rate in evaluable MCC patients was 21%. The trial has seen a majority of treatment-related adverse events classified as mild, with two serious cases reported.
Exicure, a leader in gene regulatory therapeutics, has announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 2:30 PM ET. During the event, Exicure will also host one-on-one investor meetings. The company is known for its Spherical Nucleic Acid technology and is developing treatments for various diseases, including neurology and immuno-oncology. Notably, Exicure is working on XCUR-FXN for Friedreich’s ataxia and cavrotolimod (AST-008) for advanced solid tumors.
Ipsen and Exicure Inc. have entered a collaboration to develop novel Spherical Nucleic Acids (SNAs) targeting Huntington’s disease and Angelman syndrome. Ipsen will pay Exicure $20 million upfront, with potential for up to $1 billion in milestone payments and royalties. SNAs are expected to enhance drug delivery to hard-to-reach areas like the brain. Both diseases currently lack approved disease-modifying therapies, presenting a significant market opportunity. The partnership aims to leverage Ipsen's expertise in neuroscience and Exicure's innovative delivery technology to address these unmet medical needs.